Liquid Embolic Volume Does Not Predict Outcome After Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
Authors:
- Abdulrhman AlsalamaAAAbdulrhman Alsalama
- Bluyé DeMessieBDBluyé DeMessie
- Muhammed Amir EssibayiMEMuhammed Amir Essibayi
- Gaultier MarnatGMGaultier Marnat
- Hamza Adel SalimHamza Adel Salim
- Alireza KarandishAKAlireza Karandish
- Nimer AdeebNANimer Adeeb
- Dhairya A. LakhaniDLDhairya A. Lakhani
- Yan-Lin LiYLYan-Lin Li
- Diego Alejandro OrtegaDODiego Alejandro Ortega
- Joseph CarnevaleJCJoseph Carnevale
- Atakan OrscelikAOAtakan Orscelik
Open Access
- 15 October 2026
- journal article
- research article
- Published by Springer Nature in Clinical Neuroradiology
- p. 1-14
Abstract
Purpose: Middle meningeal artery embolization (MMAE) is increasingly used for chronic subdural hematoma (CSDH), but the relationship between injected liquid-embolic volume and outcomes is unclear. We evaluated dose–outcome associations and searched for a minimum effective dose. Methods: This retrospective multicenter cohort included 313 patients treated with liquid embolic agents at 12 MESH Registry centers from 2016 to 2024. MMAE was performed alone in 172 patients (55.0%) and adjunctively with surgical evacuation in 141 (45.0%). Dose was assessed as total injected volume per patient and normalized to middle meningeal artery diameter, baseline hematoma thickness, and estimated hematoma volume. The primary outcome was a 180-day composite of retreatment, residual or recurrent hematoma > 10 mm, or death. Logistic regression with multiple imputation, restricted cubic splines, and sensitivity analyses evaluated associations and nonlinearity. Results: Median injected volume was 0.60 mL (interquartile range, 0.50–0.90). Center accounted for 44.5% of variation in log volume, whereas hematoma burden accounted for 0.3%. No dose metric was significantly associated with the primary outcome or 90-day recurrence/reoperation. For absolute volume, the odds ratio per interquartile-range increment was 0.80 (95% confidence interval, 0.56–1.16; p = 0.24). No reliable minimum effective dose was identified. Findings remained consistent across sensitivity analyses and treatment indications (interaction p = 0.30). Procedural complications occurred in 6.4% and were not dose-associated. Conclusion: Within the observed range, injected volume alone was not a consistent determinant of outcome and should not be a procedural target after a satisfactory angiographic endpoint. Future studies should evaluate embolic distribution, distal penetration, and vascular territory coverage.Keywords
This publication has 20 references indexed in Scilit:
- Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal ArteryJAMA, 2026
- Does the volume of Onyx injected influence outcomes after middle meningeal artery embolization for subdural hematoma?Journal of Clinical Neuroscience, 2025
- Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After SurgeryJAMA, 2025
- Embolization of the Middle Meningeal Artery for Chronic Subdural HematomaNew England Journal of Medicine, 2025
- Adjunctive Middle Meningeal Artery Embolization for Subdural HematomaNew England Journal of Medicine, 2024
- Middle Meningeal Artery Embolization for Nonacute Subdural HematomaNew England Journal of Medicine, 2024
- Onyx dilution reduces time to resolution of chronic subdural hematomas after middle meningeal artery embolizationJournal of NeuroInterventional Surgery, 2024
- Liquid embolic surface area as a predictor of chronic subdural hematoma resolution in middle meningeal artery embolizationJournal of NeuroInterventional Surgery, 2023
- Middle Meningeal Artery Embolization with Isolated Use of Coils for Treatment of Chronic Subdural Hematomas: A Case SeriesWorld Neurosurgery, 2022
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society Series B: Statistical Methodology, 1995